This is a working overview of metabolic research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-20. Anything still debated is marked as such rather than presented as settled.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
P2Y purinoceptor 13 is a protein that in humans is encoded by the P2RY13 gene. The product of this gene, P2Y13, belongs to the family of G-protein coupled receptors. This family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. This receptor is activated by ADP. Two transcript variants encoding the same protein have been identified for this gene.
Siddhartha Roy (born 1 April 1954) is an Indian Chemical and Structural biologist, biophysicist, former director of the Indian Institute of Chemical Biology and the former director (officiating) of Bose Institute. Widely known for his studies on Gene Regulation, Peptidomimetics, bacteriophage lambda and protein synthesis, he is an elected fellow of the Indian Academy of Sciences and the Indian National Science Academy. In 1999, the Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, for his contributions to Biological sciences.
=== Ancient origins === The Taurini were an ancient Celto-Ligurian, Alpine people, who occupied the upper valley of the River Po, in the centre of modern Piedmont. In 218 BC, they were attacked by Hannibal as he was allied with their long-standing enemies, the Insubres. The Taurini chief town (Taurasia) was captured by Hannibal's forces after a three-day siege. As a people they are rarely mentioned in history. It is believed that a Roman colony was established after 28 BC under the name of Julia Augusta Taurinorum (modern Turin). Both Livy and Strabo mention the Taurini's country as including one of the passes of the Alps, which points to a wider use of the name in earlier times.
== Use as a watermark == In 2010, when Craig Venter unveiled the first fully functioning, reproducing cell controlled by synthetic DNA he described how his team used frequent stop codons to create watermarks in RNA and DNA to help confirm the results were indeed synthetic (and not contaminated or otherwise), using it to encode authors' names and website addresses.
Sources: en.wikipedia.org
In phase one, the dosages of noggin, a regulator protein, as well as rhBMP-2 were properly calibrated, and in phase two these proteins carried on synthetic calcium phosphate matrix (CPM) were then injected into the ACL region. The results of this procedure also demonstrated an improvement in the collagen fiber formation between the tendon and the bone. Hence, all three treatments were seen to improve the efficacy of tendon-to-bone healing via the different bone growth factors: SHMSP, bone protein, and rhBMP-2.
Women in the Mexican drug war have been participants and civilians. They have served for or been harmed by all belligerents. There have been female combatants in the military, police, cartels, and gangs. Women officials, judges, prosecutors, lawyers, paralegals, reporters, business owners, social media influencers, teachers, and non-governmental organizations directors and workers have also been involved in different capacities. Women citizens and foreigners, including migrants, have been raped, tortured, and murdered in the conflict. Cartels and gangs fighting in the conflict carry out sex trafficking in Mexico as an alternative source of profits. Some members of criminal organizations also abduct women and girls for sexual slavery and carry out sexual assault of migrants from Latin America to the United States. Groups of women known as madres buscadoras ('searching mothers') have become prominent for organizing searches for disappeared relatives, and their work has uncovered unmarked mass graves that provide evidence of widespread disappearances.
== Research and teaching == Strobel's research focuses on the biophysics and biochemistry of catalytic RNAs, including riboswitches and peptidyl transferase. His group developed the early methods of Nucleotide Analog Interference Mapping, used to determine the importance of particular functional groups in a structured RNA molecule. Strobel's group solved the x-ray crystal structure of the full length Azoarcus Group I catalytic intron, the glmS ribozyme, and the c-di-GMP riboswitch. He has also collaborated with the Thomas A. Steitz lab at Yale on structural studies toward better understanding the mechanism of ribosomal peptide synthesis. He was twice named a HHMI professor to promote undergraduate science education. With this award he instituted an undergraduate research course, the Rainforest Expedition and Laboratory, which explored microbial and chemical diversity in the world's rainforests as a means to inspire undergraduate students in the sciences. He has led groups of undergraduate students into the rainforest over spring break to hunt for novel endophytes that live inside plants. Following fieldwork, students then isolated microbes and tested them for interesting properties, discovering a variety of organisms including novel fungi with new biological and chemical properties, including Pestalotiopsis microspora, of which some strains degrade polyurethane.
Sources: en.wikipedia.org
Biden left office on January 20, 2017, and was succeeded by the 48th vice president of the United States, Mike Pence. After leaving the vice presidency, Biden became an honorary professor at the University of Pennsylvania, developing the Penn Biden Center for Diplomacy and Global Engagement. Biden remained in that position until 2019. In 2017, Biden wrote a memoir, Promise Me, Dad, and went on a book tour. By 2019, he and his wife reported that they had earned over $15 million since the end of his vice presidency from speaking engagements and book sales. Biden remained in the public eye, endorsing candidates while continuing to comment on politics, climate change, and the presidency of Donald Trump. He also continued to speak out in favor of LGBT rights, continuing advocacy on an issue he had become more closely associated with during his vice presidency. In 2018, he gave a eulogy for Senator John McCain. Biden continued to support cancer research.
This is significant because any patient with tardive dyskinesia was specifically excluded from randomization to perphenazine; i.e., in the CATIE study the patient cohort randomized to receive perphenazine was at lower risk of having extrapyramidal symptoms. Atypical antipsychotics do not appear to lead to improved rates of medication adherence compared to typical antipsychotics. Many researchers question the first-line prescribing of atypicals over typicals, and some even question the distinction between the two classes. In contrast, other researchers point to the significantly higher risk of tardive dyskinesia and other extrapyramidal symptoms with the typicals and for this reason alone recommend first-line treatment with the atypicals, notwithstanding a greater propensity for metabolic adverse effects in the latter. The UK government organization NICE recently revised its recommendation favoring atypicals, to advise that the choice should be an individual one based on the particular profiles of the individual drug and on the patient's preferences. The re-evaluation of the evidence has not necessarily slowed the bias toward prescribing the atypicals.
== Condensation polymerization == Step-growth polymerization and condensation polymerization are two different concepts, not always identical. In fact polyurethane polymerizes with addition polymerization (because its polymerization produces no small molecules), but its reaction mechanism corresponds to a step-growth polymerization. The distinction between addition polymerization and condensation polymerization was introduced by Wallace Carothers in 1929, and refers to the type of products, respectively:
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.